DUBLIN, May 4, 2021 /PRESSDAILY.COM/ — The “Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026” report has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insight on clinical and non-clinical factors that are driving the global C5 Complement Inhibitors market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 3 commercially available C5 Complement Inhibitors with their regional level revenue, market share and the clinical profile.

Report Highlights:

  • Global C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion
  • Global C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)
  • Global C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)
  • Commercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)
  • Soliris (Eculizumab) Sales In 2020: > USD 3 Billion

Global pharmaceutical marketplace is undergoing subtle changes with respect to the need of the patient population. The entire pharmaceutical industry is packed with effective therapeutics against different types of diseases and eventually the availability of hundreds of therapies and thousands of therapeutic agents in the commercial market has eventually made the global pharmaceutical market worth trillion-dollar size. Although, the global pharmaceutical market is packed with excessive number of therapies, but for the development of the market to an extensive level, researchers have come across with a novel and impressive therapeutic class known as C5 complement inhibitor therapy which targets one of the most important immune system pathways.

The arrival of C5 complement inhibitor drug market for the need of the patient population all over the world is believed to be capable of bearing all the challenges that the pharmaceutical industry has been witnessing for long period of time. Not only cancer, but the therapeutic approach developed by the researchers few years back is believed to be having subtle impact on several different kidney diseases and many more that have huge mortality rate. Over a small period of time, the respective therapeutic approach is also being focused by some of the big pharmaceutical players which indeed have led to a traditional increase in the rate of research and development activities for the same.

It is predicted that in the next few years of time period, the entire therapeutic approach which at the current period of time is only having few clinical drugs will be packed with excessive number of inhibitors, driving the way of the respective therapy market to become one of the pioneering leaders. Some of the parameters that are estimated to get improved with coming time for the substantial improvement of the overall therapy are: R&D productivity, inhibitor cost reduction, as well as influx of major pharmaceutical players and biotech companies, focused towards adapting the therapeutic approach for further investigation against different diseases with high mortality and prevalence rate.

The report predicts that the therapeutic approach despite of being completely novel, when compared with other old and traditional therapies is accelerating at a very high rate with respect to market size and opportunities. In addition, the global sales of the C5 complement inhibitor drug market is growing at steadily, apparently depicting the increase in the consumption rate of the drugs by the patients. Exclusive demand of the therapeutic approach such as C5 complement inhibitor therapy and the presence of few inhibitor drugs in the market is also predicted to align the entire market toward becoming more dynamic and drastic. It is predicted that in the next few years, several investigational drugs will enter late-stage clinical development phase, which will eventually cause a projectile inclination in the rate of market growth and opportunities highly lacking in the current pharmaceutical industry.

Key Topics Covered:

1. Introduction to C5 Complement Inhibitors
1.1 Overview
1.2 Evolution of C5 Complement Inhibitors

2. Mechanism of C5 Complement Inhibitors
2.1 Mechanism of Complement Activation
2.2 Inhibition of C5 Complement

3. Global C5 Complement Inhibitors Market Sales Insight
3.1 Current Market Scenario
3.2 Future Market Opportunity
3.3 Market Opportunity by Indication
3.3.1 Paroxysmal Nocturnal Hemoglobinuria
3.3.2 Atypical Hemolytic Uremic Syndrome
3.3.3 Neuromyelitis Optica Spectrum Disorder
3.3.4 Generalized Myasthenia Gravis

4. Global C5 Complement Inhibitors Clinical Trials Overview
4.1 By Company
4.2 By Country
4.3 By Patient Segment
4.4 By Phase

5. US – C5 Complement Inhibitors Market Analysis
5.1 Current Market Scenario
5.2 Future Market Opportunity

6. Europe – C5 Complement Inhibitor Market Analysis
6.1 Current Market Scenario
6.2 Future Market Opportunity

7. Asia Pacific – C5 Complement Inhibitor Market Analysis
7.1 Current Market Scenario
7.2 Future Market Opportunity

8. Soliris (Eculizumab)
8.1 Overview
8.2 Patent Exclusivity & Designations
8.3 Dosage & Price Analysis
8.3.1 Branded (Soliris)
8.3.2 Biosimilar (Elizaria)
8.4 Global Sales Analysis
8.5 Soliris Regional Sales Analysis
8.5.1 US
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 Rest of World

9. Ultomiris (Ravulizumab)
9.1 Overview
9.2 Patent Exclusivity & Designation
9.3 Dosage & Price Analysis
9.4 Global Sales Analysis
9.5 Soliris Regional Sales Analysis
9.5.1 US
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Rest of World

10. Global C5 Complement Inhibitors Clinical Trials Insight
10.1 Preclinical
10.2 Phase-I
10.3 Phase-II
10.4 Phase-II/III
10.5 Phase-III

11. Marketed C5 Complement Inhibitors Clinical Insight
11.1 Eculizumab
11.2 Ravulizumab
11.3 Eculizumab Biosimilar

12. C5 Complement Inhibitors Market Dynamics
12.1 C5 Complement Inhibitors Market Drivers
12.2 Challenges for C5 Complement Inhibitor Market

13. C5 Complement Inhibitor Market Future Outlook

14. Competitive Landscape
14.1 Amgen
14.2 Akari Therapeutics
14.3 CANbridge Pharmaceuticals
14.4 ChemoCentryx
14.5 Generium
14.6 IVERIC Bio
14.7 Novartis
14.8 Roche
14.9 Samsung Bioepis
14.10 UCB

For more information about this report visit https://www.researchandmarkets.com/r/h28x2m

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links



Generosa Delgado has been a health writer for Press Daily since 2018. Previously, she was a health and medical writer for The Los Angeles Times. Generosa has experience working as a freelance journalist since 2016, and before that as a staff writer for Health Magazine.